NFL BIOSCIENCES: NEW PATENT APPLICATION ASSOCIATING NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS
November 02 2022 - 3:00AM
NFL BIOSCIENCES: NEW PATENT APPLICATION ASSOCIATING NFL-101 WITH
OTHER SMOKING CESSATION TREATMENTS
NFL BIOSCIENCES: NEW PATENT APPLICATION ASSOCIATING NFL-101 WITH
OTHER SMOKING CESSATION TREATMENTS
NFL BIOSCIENCES (Euronext Growth Paris –
FR0014003XT0 – ALNFL), a biopharmaceutical company developing
botanical drugs for the treatment of addictions,
announces it has submitted a new patent
application to protect the administration of NFL-101 in
association with other smoking
cessation treatments, and
particularly nicotine replacement
therapies. The application was initially submitted
in the United States and will be extended to cover other countries
in line with the intellectual property protection strategy put in
place by NFL Biosciences.
NFL Biosciences intends to demonstrate the
benefits of associating NFL-101 with other smoking cessation
treatments and particularly nicotine replacement therapies: with
the launch of dedicated clinical trials, NFL Biosciences has
submitted a patent application to protect the administration of
NFL-101 before an attempt to stop smoking at the same time as
commencing another smoking cessation treatment and especially
nicotine replacement therapies.
Nicotine substitutes include transdermal
patches, tablets, chewing gums, inhalers and nicotine sprays. They
are used as a substitute for cigarettes after stopping smoking or
reducing the number of cigarettes consumed in order to mitigate the
withdrawal symptoms due to reduced or zero nicotine intake.
The global market for smoking cessation drugs is
estimated at nearly USD 6 billion (source: Coherent Market
Insights); with an estimated growth of 6% for the coming years. The
market potential is nevertheless limited by a lack of more
effective treatments without side effects. Despite a modest level
of efficacy after six months, at around 15.7% (source: EAGLES1),
nicotine replacement therapies make up 80% of the market. They are
the leading treatments, because they do not have any significant
side effects, while other drugs such as Champix®/Chantix® and
Zyban®, which have slightly higher efficacy levels (also after six
months and according to EAGLES: 21.8% for Champix/Chantix and 16.2%
for Zyban), are sometimes poorly tolerated.
Bruno Lafont, Chief Operating Officer and
co-founder of NFL Biosciences: “Improving the efficacy of smoking
cessation treatments and specifically nicotine substitutes without
generating side effects represents a major challenge. In addition
to the CESTO 2 clinical trial that is underway for NFL-101
administered alone, this patent application represents the first
milestone with our commitment to demonstrating the benefits of
associating NFL-101 with other treatments and particularly nicotine
replacement therapies. Once on the market, NFL-101 would then have
a major competitive advantage because it could be prescribed either
on its own or in association with other treatments in order to
increase their efficacy”.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company
based in the Montpellier area which develops botanical drug
candidates for the treatment of addictions. NFL Biosciences'
ambition is to bring new, natural, safer and more effective
therapeutic solutions to the entire world population, including
low- and middle-income countries. Its most advanced product, called
NFL-101, is a standardized, nicotine-free tobacco leaf extract
protected by two patent families. NFL Biosciences intends to offer
smokers who want to quit a natural, safe, easy-to-administer and
personalized alternative. NFL Biosciences is also developing
NFL-301, a natural drug candidate for the reduction of alcohol
consumption and has a drug development project for the treatment of
cannabis use disorders.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com
Contacts
Bruno Lafont – info@nflbiosciences.com - +33 4
11 93 76 67 Agence
Calyptus – nflbio@calyptus.net - +33 1 53 65 68 68
1 EAGLES (Evaluating Adverse Events in a Global
Smoking Cessation Study) is one of the biggest studies carried out
on smoking cessation treatments. Multinational, randomized and
double blind, it covered 8,058 smokers. The findings were published
in 2018 in the Journal of the American Medical Association.
- 20221102_NFLBiosciences_Dépot-brevet-NFL101-TNS_EN_DEF
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Oct 2024 to Nov 2024
NFL Biosciences (EU:ALNFL)
Historical Stock Chart
From Nov 2023 to Nov 2024
